Biosimilars: a cheaper and efficient alternative to name-brand drugs
IN PARTNERSHIP WITH THE EUROPEAN COMMISSION
'The silent pandemic': How is the EU facing Antimicrobial Resistance?
IN PARTNERSHIP WITH THE EUROPEAN COMMISSION
Video. Biosimilars: a cheaper and efficient alternative to name-brand drugs
In partnership with
The European Commission
The European Commission's pharmaceutical reform would improve access to cheaper biosimilar medicines and speed up the time it takes to access the market.
Read full article
